After a rigorous characterization of our HER2-positive breast cancer model, we especially investigated the HER2 protein binding affinity of our nanoprobes SPION-Cy-PEG-scFv, their cellular uptake and in vivo tumor targeting. Here, ERBB2 is linked to neoplasm.